BioAtla
Safer, more effective drugs for cancer using a proprietary next generation antibody discovery and evolution platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 1345.0x EV/Revenue -19.9x EV/EBITDA | round | |
| investor investor investor investor investor investor | €0.0 | round | |
* | $65.0m | Post IPO Equity | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (51 %) | (92 %) | (42 %) | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (256 %) | (525 %) | (6758 %) | (37904 %) | - | - | (671 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (273 %) | (573 %) | (8357 %) | (38161 %) | - | - | (634 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 248 % | 498 % | 4646 % | 23310 % | - | - | 574 % |
Source: Company filings or news article
Related Content
BioAtla, based in San Diego, is a pioneering biopharmaceutical company focused on creating innovative cancer treatments. The company specializes in developing monoclonal antibody and cell-based therapeutics through its proprietary Conditionally Active Biologics (CAB) platform. This technology leverages the unique microenvironment of diseased tissue to target cancer more effectively, thereby improving the therapeutic index and safety profile of its drugs. BioAtla serves the oncology market, primarily targeting patients with solid tumors. The company operates on a business model that includes research and development, clinical trials, and partnerships with other biotech firms and healthcare providers. Revenue is generated through licensing agreements, milestone payments, and eventual product sales.
Keywords: biopharmaceutical, cancer therapy, monoclonal antibodies, cell-based therapeutics, CAB platform, oncology, solid tumors, clinical trials, biotechnology, San Diego.
